Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $298.61

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty-five analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $298.61.

A number of equities research analysts have commented on ALNY shares. Wolfe Research cut Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a report on Tuesday, November 12th. TD Cowen increased their price objective on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Sanford C. Bernstein cut their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. Barclays raised their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an "overweight" rating in a research note on Friday, November 1st. Finally, HC Wainwright reissued a "buy" rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, January 13th.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock traded up $3.17 during trading hours on Thursday, hitting $277.16. The stock had a trading volume of 561,203 shares, compared to its average volume of 689,978. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39. The stock has a market capitalization of $35.75 billion, a price-to-earnings ratio of -105.79 and a beta of 0.34. The stock's fifty day moving average is $249.42 and its two-hundred day moving average is $260.65. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analysts' expectations of $532.91 million. The company's quarterly revenue was down 33.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.15 EPS. As a group, analysts predict that Alnylam Pharmaceuticals will post -2.24 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the company's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares of the company's stock, valued at $3,310,677.18. This represents a 10.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 5,219 shares of the firm's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the sale, the chief executive officer now owns 78,880 shares of the company's stock, valued at $19,797,302.40. This represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 73,964 shares of company stock valued at $20,622,925 over the last quarter. Company insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Huntington National Bank increased its stake in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter worth $29,000. R Squared Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $33,000. Washington Trust Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $42,000. Finally, True Wealth Design LLC grew its stake in Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 153 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.